IL17A and neoplasm: Bie et al. combined IL-17 with tumor growth inhibitors for the long-term abrogation of IL-17RB-expressing CSC production, which strongly inhibited tumor growth in vivo.325 This finding validates the possibility of using IL-17RB as a target cell marker for cancer therapy, and provides a novel immunotherapy strategy for cancer treatment.